2.26
1.80%
+0.04
After Hours:
2.20
-0.06
-2.65%
Processa Pharmaceuticals Inc stock is currently priced at $2.26, with a 24-hour trading volume of 85,086.
It has seen a +1.80% increased in the last 24 hours and a -11.02% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $2.21 pivot point. If it approaches the $2.34 resistance level, significant changes may occur.
Previous Close:
$2.22
Open:
$2.26
24h Volume:
85,086
Market Cap:
$6.45M
Revenue:
-
Net Income/Loss:
$-11.12M
P/E Ratio:
-1.5586
EPS:
-1.45
Net Cash Flow:
$-8.07M
1W Performance:
-7.00%
1M Performance:
-11.02%
6M Performance:
-66.86%
1Y Performance:
-83.13%
Processa Pharmaceuticals Inc Stock (PCSA) Company Profile
Name
Processa Pharmaceuticals Inc
Sector
Industry
Phone
443 776 3133
Address
7380 Coca Cola Drive, Suite 106, Hanover
Processa Pharmaceuticals Inc Stock (PCSA) Latest News
Spotting Penny Stocks Uptrends, 3 Top Tips
PennyStocks
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
GlobeNewswire Inc.
Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting
GlobeNewswire Inc.
Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
GlobeNewswire Inc.
Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference
GlobeNewswire Inc.
Processa Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
Benzinga
Processa Pharmaceuticals Inc Stock (PCSA) Financials Data
Processa Pharmaceuticals Inc (PCSA) Net Income 2024
PCSA net income (TTM) was -$11.12 million for the quarter ending December 31, 2023, a +59.45% increase year-over-year.
Processa Pharmaceuticals Inc (PCSA) Cash Flow 2024
PCSA recorded a free cash flow (TTM) of -$8.07 million for the quarter ending December 31, 2023, a +16.02% increase year-over-year.
Processa Pharmaceuticals Inc (PCSA) Earnings per Share 2024
PCSA earnings per share (TTM) was -$8.88 for the quarter ending December 31, 2023, a +73.77% growth year-over-year.
Processa Pharmaceuticals Inc Stock (PCSA) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Young David | Pres. Research & Development |
Feb 06 '24 |
Buy |
2.53 |
20,000 |
50,504 |
58,387 |
Lin Patrick | Chief Business - Strategy Off |
Feb 01 '24 |
Buy |
2.40 |
1,500 |
3,600 |
27,478 |
Lin Patrick | Chief Business - Strategy Off |
Jan 31 '24 |
Buy |
2.37 |
2,500 |
5,925 |
25,978 |
Ng George K | Chief Executive Officer |
Jan 30 '24 |
Buy |
2.70 |
10,000 |
27,000 |
20,000 |
Yorke Justin W | Director |
Jan 30 '24 |
Buy |
2.69 |
8,000 |
21,544 |
31,232 |
Young David | President & CEO |
Jun 12 '23 |
Buy |
0.80 |
40,000 |
32,000 |
470,424 |
About Processa Pharmaceuticals Inc
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.
Cap:
|
Volume (24h):